Keywords: Novartis, Jetrea, Ocriplasmin, Vitreomacular traction, ThromboGenics, Alcon, Ph III

Ph III trials show Novartis' Jetrea improves vitreomacular traction

Article | 17 August 2012

Print This

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published positive results of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in